Jagat Pharma & Dr Basu Group endeavours for 250+ Cr revenue by FY 2027

The company is actively preparing to enter the lucrative markets of the Middle East and African countries

Jagat Pharma, a trusted name in Ayurvedic wellness, is poised for remarkable growth as it targets revenue exceeding Rs 250 crore by the financial year 2027. Renowned for its expertise in Ayurvedic eye care and wellness products, the company has steadily expanded its reach across India and beyond, combining a legacy of over 42 years with innovative strategies.

The company has an impressive reach in the offline space also, with over 200 distributors across 17+ states. This includes a strong presence in South India with 50+ distributors for a territory that is embracing Ayurvedic solutions in increasing folds. With yearly 200 per cent growth, its online space dominance gives it a 60 per cent market share in the Ayurvedic eye care segment as well. The company makes its products available to millions of customers across the country by using this comprehensive dual-channel strategy.

Jagat Pharma’s ambitious expansion plans extend far beyond Indian borders. The company is actively preparing to enter the lucrative markets of the Middle East and African countries, tapping into regions with a rising demand for holistic healthcare solutions. A significant milestone in its international journey is its imminent entry into the United States, with exports slated to begin in December 2024. This step is backed by Jagat Pharma’s commitment to quality and compliance, as evidenced by its recent USFDA certification. Combined with its existing WHO-GMP certification, the company is well-positioned to meet the stringent global standards required to compete in international markets.